Oct 10, 2025 06:07AM BTIG Starts Perspective Therapeutics Inc (CATX) at Buy, PT $14

Oct 4, 2025 04:00PM Why UBS says Q4 is eventful for SMID oncology stocks

Oct 3, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Perspective Therapeutics Inc (CATX)

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Aug 22, 2025 07:47AM UBS Reiterates Buy Rating on Perspective Therapeutics Inc (CATX)

Aug 13, 2025 12:58PM Perspective Therapeutics Inc (CATX) PT Lowered to $14 at Oppenheimer

Aug 13, 2025 07:08AM Perspective Therapeutics, Inc. (CATX) Reports In-Line Q2 EPS

Jul 24, 2025 12:46PM Perspective Therapeutics data accepted for ESMO Congress presentation

Jun 3, 2025 05:05AM Perspective Therapeutics Inc (CATX) PT Raised to $16 at RBC Capital

May 30, 2025 06:46AM Cantor Fitzgerald Reports Key Takeaways from Call With RadioMedia CEO

May 30, 2025 06:45AM Cantor Fitzgerald reports key Takeaways from call with RadioMedia CEO

May 13, 2025 07:20AM Perspective Therapeutics, Inc. (CATX) Tops Q1 EPS by 6c

May 13, 2025 04:56AM Perspective Therapeutics Inc (CATX) PT Lowered to $15 at Oppenheimer

Apr 7, 2025 11:29AM Perspective Therapeutics Inc (CATX) PT Lowered to $10 at Truist Securities

Mar 27, 2025 11:01AM Perspective Therapeutics Inc (CATX) PT Lowered to $15 at RBC Capital

Mar 27, 2025 06:51AM Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)

Mar 17, 2025 07:07AM Perspective Therapeutics (CATX) Announces First Patient Dosed with VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 7, 2025 07:12AM Scotiabank Starts Perspective Therapeutics Inc (CATX) at Sector Outperform

Jan 27, 2025 04:26PM Perspective Therapeutics Inc (CATX) PT Raised to $20 at Lucid Capital Markets

Nov 25, 2024 06:23AM Perspective Therapeutics Inc (CATX) PT Lowered to $16 at RBC Capital

Nov 23, 2024 09:58AM BofA Securities Downgrades Perspective Therapeutics Inc (CATX) to Neutral

Nov 12, 2024 04:10PM Perspective Therapeutics, Inc. (CATX) Reports In-Line Q3 EPS

Oct 24, 2024 03:50AM UBS Starts Perspective Therapeutics Inc (CATX) at Buy

Oct 21, 2024 06:46AM Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)

Oct 14, 2024 06:07AM Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)

Oct 11, 2024 02:19PM Truist Securities Reiterates Buy Rating on Perspective Therapeutics Inc (CATX)

Oct 11, 2024 06:24AM Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)

Sep 25, 2024 06:20AM Truist Securities Starts Perspective Therapeutics Inc (CATX) at Buy

Aug 16, 2024 06:26AM Perspective Therapeutics Inc (CATX) PT Lowered to $27 at RBC Capital

Aug 13, 2024 07:51AM Perspective Therapeutics Inc (CATX) PT Lowered to $17 at Oppenheimer

Aug 12, 2024 04:40PM Perspective Therapeutics, Inc. (CATX) Misses Q2 EPS by 16c

Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time

Jul 25, 2024 07:35AM BofA Securities Starts Perspective Therapeutics Inc (CATX) at Buy

Jun 18, 2024 07:26AM Perspective Therapeutics Inc (CATX) PT Raised to $19 at Oppenheimer

Jun 14, 2024 06:20AM RBC Capital Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)

Jun 11, 2024 07:02AM Perspective Therapeutics (CATX) Announces 1-for-10 Reverse Stock Split